BioAdvance News

pH Pharma and Immunome Enter into Collaboration and License Agreement to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates in Oncology

By WebmasterOctober 21, 2019November 1st, 2024No Comments

pH Pharma and Immunome Enter into Collaboration and License Agreement to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates in Oncology

See more here

Previous PostTmunity and Oncora Medical Partner to Advance the Use of Real-World Data to Accelerate the Availability of CAR-T Therapies for Cancer Patients
Next PostRelmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression

pH Pharma and Immunome Enter into Collaboration and License Agreement to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates in Oncology

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostTmunity and Oncora Medical Partner to Advance the Use of Real-World Data to Accelerate the Availability of CAR-T Therapies for Cancer Patients

Next PostRelmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression